Dogwood Therapeutics Inc
DWTX4.910USD
+0.060+1.24%
Market hours （ET）Quotes delayed by 15 min
9.38MMarket Cap
LossP/E TTM
More Details of Dogwood Therapeutics Inc Company
Dogwood Therapeutics, Inc., formerly Virios Therapeutics, Inc., is focused on the clinical development of three assets, Halneuron, IMC-1, and IMC-2. Halneuron is in Phase 2b development as a non-opioid, Nav 1.7 inhibitor, to treat the neuropathic pain associated with chemotherapy treatment. Halneuron is an injectable formulation of Tetrodotoxin, a novel small molecule with action exclusively on the peripheral nervous system. IMC-2 (valacyclovir + celecoxib) is in Phase 2 development as a combination antiviral treatment for Long-COVID (LC). IMC-1 (famciclovir (FM) + celecoxib) is Phase 3 development ready as a combination antiviral treatment for FM. IMC-1 has been granted fast track designation by the FDA. IMC-1 is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms.
Company Info
Ticker SymbolDWTX
Company nameDogwood Therapeutics Inc
IPO dateDec 17, 2020
CEOMr. Gregory Scott (Greg) Duncan
Number of employees12
Security typeOrdinary Share
Fiscal year-endDec 17
Address44 Milton Avenue
CityALPHARETTA
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code30009
Phone18666208655
Websitehttps://dwtx.com/
Ticker SymbolDWTX
IPO dateDec 17, 2020
CEOMr. Gregory Scott (Greg) Duncan
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Gregory Scott (Greg) Duncan
Mr. Gregory Scott (Greg) Duncan
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.30K
--
Dr. Abel De La Rosa, Ph.D.
Dr. Abel De La Rosa, Ph.D.
Independent Director
Independent Director
160.00
--
Ms. Angela Walsh
Ms. Angela Walsh
Chief Financial Officer
Chief Financial Officer
120.00
--
Dr. Richard James (Rich) Whitley, M.D.
Dr. Richard James (Rich) Whitley, M.D.
Independent Director
Independent Director
28.00
--
Mr. Ralph Grosswald
Mr. Ralph Grosswald
Senior Vice President - Operations
Senior Vice President - Operations
--
--
Dr. R. Michael (Mike) Gendreau, M.D., Ph.D.
Dr. R. Michael (Mike) Gendreau, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Alan Yu
Mr. Alan Yu
Director
Director
--
--
Mr. John C. Thomas, Jr.
Mr. John C. Thomas, Jr.
Independent Director
Independent Director
--
--
Mr. David (Rick) Keefer
Mr. David (Rick) Keefer
Independent Director
Independent Director
--
--
Mr. Melvin Toh
Mr. Melvin Toh
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Gregory Scott (Greg) Duncan
Mr. Gregory Scott (Greg) Duncan
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.30K
--
Dr. Abel De La Rosa, Ph.D.
Dr. Abel De La Rosa, Ph.D.
Independent Director
Independent Director
160.00
--
Ms. Angela Walsh
Ms. Angela Walsh
Chief Financial Officer
Chief Financial Officer
120.00
--
Dr. Richard James (Rich) Whitley, M.D.
Dr. Richard James (Rich) Whitley, M.D.
Independent Director
Independent Director
28.00
--
Mr. Ralph Grosswald
Mr. Ralph Grosswald
Senior Vice President - Operations
Senior Vice President - Operations
--
--
Dr. R. Michael (Mike) Gendreau, M.D., Ph.D.
Dr. R. Michael (Mike) Gendreau, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Aug 1
Updated: Fri, Aug 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
CK Life Sciences International Holdings, Inc.
11.06%
Orca Capital GmbH
3.65%
Corday (Brian David)
1.85%
UBS Financial Services, Inc.
1.54%
Geode Capital Management, L.L.C.
0.75%
Other
81.14%
Shareholders
Shareholders
Proportion
CK Life Sciences International Holdings, Inc.
11.06%
Orca Capital GmbH
3.65%
Corday (Brian David)
1.85%
UBS Financial Services, Inc.
1.54%
Geode Capital Management, L.L.C.
0.75%
Other
81.14%
Shareholder Types
Shareholders
Proportion
Corporation
11.06%
Investment Advisor
6.45%
Individual Investor
2.01%
Investment Advisor/Hedge Fund
1.41%
Hedge Fund
0.05%
Bank and Trust
0.02%
Research Firm
0.01%
Other
78.98%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
47
389.22K
20.37%
+58.94K
2025Q1
54
438.08K
23.17%
+71.69K
2024Q4
56
318.28K
23.89%
+153.45K
2024Q3
56
145.37K
13.24%
-84.77K
2024Q2
59
142.25K
12.98%
-112.94K
2024Q1
57
129.92K
15.13%
-123.53K
2023Q4
55
153.94K
20.42%
-96.99K
2023Q3
59
153.21K
20.69%
-93.94K
2023Q2
60
150.32K
20.53%
-85.72K
2023Q1
57
149.50K
20.53%
-85.07K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
CK Life Sciences International Holdings, Inc.
211.38K
11.06%
--
--
Apr 15, 2025
Orca Capital GmbH
69.82K
3.65%
+69.82K
--
Mar 14, 2025
Corday (Brian David)
35.30K
1.85%
-17.35K
-32.95%
Feb 13, 2024
UBS Financial Services, Inc.
29.46K
1.54%
+11.79K
+66.69%
Mar 31, 2025
Geode Capital Management, L.L.C.
14.41K
0.75%
+3.48K
+31.79%
Mar 31, 2025
The Vanguard Group, Inc.
11.78K
0.62%
+11.78K
--
Mar 31, 2025
HRT Financial LP
11.23K
0.59%
+11.23K
--
Mar 31, 2025
Duncan (Gregory Scott)
2.30K
0.12%
--
--
Apr 15, 2025
Tower Research Capital LLC
1.05K
0.05%
+78.00
+8.02%
Mar 31, 2025
Morgan Stanley Smith Barney LLC
600.00
0.03%
--
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 07, 2024
Merger
25<1
Oct 07, 2024
Merger
25<1
Oct 07, 2024
Merger
25<1
Oct 07, 2024
Merger
25<1
Date
Type
Ratio
Oct 07, 2024
Merger
25<1
Oct 07, 2024
Merger
25<1
Oct 07, 2024
Merger
25<1
Oct 07, 2024
Merger
25<1
